Affimed

We are a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer.

[Affimed @affimed]

We are thrilled to announce Shawn M. Leland, Pharm D, RPh is @affimed's new CEO. Shawn has a proven track record in advancing cutting-edge oncology assets, securing significant capital, and negotiating global licensing agreements.

Read more here: https://t.co/lzFFW7rFXZ

#AFMD

[Affimed @affimed]

Today @affimed announced that it has received FDA Fast Track Designation for AFM13 combined w/ AB-101 for the treatment of patients with R/R Hodgkin lymphoma which will be investigated in the LuminICE-203 study (NCT05883449).

Press release: https://t.co/a8dvb8lni1

#Affimed

[Affimed @affimed]

Today at 8:30 a.m. EDT / 14:30 CET, we discuss our Q2 2023 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://t.co/8JvEoQIf4F

#AFMD

[Affimed @affimed]

Today Affimed provided details on the AFM24-101 monotherapy study in NSCLC at ASCO 2023 and provides a strategic update on the AFM24 development plan. For further details, see the full press release at: https://t.co/lIzCuesztA.

#AFMD #AFM24 #ImmunoOncology

[Affimed @affimed]

@Affimed will be hosting an investor event June 3, 2023, at 6:00 PM CDT/ 7:00 PM EDT to review AFM24 monotherapy data and provide a strategic update on the program going forward.

Webcast: https://t.co/rjfiUcUxoA
Dial in: https://t.co/oe0BEhiQ8E

#AFMD #AFM24 #InnateImmunity

[Affimed @affimed]

Affimed is pleased to announce two abstracts at EHA2023, the Annual Meeting of the European Hematology Association. Read more here https://t.co/GqEUJQZdiD
#immunooncology #AFM13 #AFM28 #EHA2023

[Affimed @affimed]

We are pleased to announce that we have dosed the first patient in our first-in-human study investigating AFM28 in patients with relapsed/refractory CD123-positive Acute Myeloid Leukemia (AML). Read the full press release here: https://t.co/ADpq2Gdiqj

[Affimed @affimed]

Today at 8:30 a.m. EDT / 13:30 CET, we discuss our full year 2022 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website. Full PR: https://t.co/x0TzkqhcJs

[Affimed @affimed]

Join us at this year’s Annual Meeting of the @AACR in Orlando, Florida! We will host an oral presentation on results from our REDIRECT study and a poster presentation on the potential of AFM13 to induce effective ADCC. To the PR: https://t.co/7G4klXxml9 #ImmunoOncology

[Affimed @affimed]

Our CEO, Adi Hoess will participate in a fireside chat at the @HCWCO Cell Therapy Conference today. Join our webcast https://t.co/5gBtVtXofA at 8:30 a.m. EST / 14:30 CET to learn more about Affimed’s approach to fighting cancer.

[Affimed @affimed]

Thank you @Cormac_Sheridan for taking the time to speak with our CMO, Dr. Andreas Harstrick, about Affimed's exciting data and the synergistic potential that ICE® molecules bring to the NK cell space. Read the article in Nature Biotechnology here: https://t.co/x9GL0PmqQg

[Affimed @affimed]

Join our CEO Adi Hoess for a fireside chat with Daina Greybosch, Ph.D., at this year's SVB Securities 2023 Global Biopharma Conference at 2:20 p.m. EST / 8:20 p.m. CET on Tuesday, February 14, 2023. To the webcast: https://t.co/dMscoTFoto

[Affimed @affimed]

Today we announced a regulatory update for #AFM13 & reported on corporate progress. Read more here https://t.co/aKjNCESXQB. #AFM13 #InnateImmunity #ImmunoOncology

[Affimed @affimed]

The French National Agency for the Safety of Medicines & Health Products has authorized a CTA for our innate cell engager (ICE®), #AFM28. This allows us to advance its clinical development to fight relapsed / refractory #AML, a severe blood cancer: https://t.co/NRk9viz6DA

[Affimed @affimed]

Today at #ASH22 we gave an update on our preclinical innate cell engager (ICE®) #AFM28, targeting CD123+ cells in diseases such as acute myeloid #leukemia. AFM28 can successfully destroy tumor cells! https://t.co/wKZNrzGbSk #WhyWeFightCancer #AffimedProud #AFM13 #InnateImmunity

[Affimed @affimed]

Today, we announced 2 important data sets: topline data from our monotherapy Phase 2 REDIRECT trial in r/r PTCL patients & data from our study with @MDAndersonNews evaluating the combination of AFM13 with NK cells. More here:https://t.co/aHFvupnUPb https://t.co/IrI3Q2ZxZg #ASH22

[Affimed @affimed]

Affimed will be hosting an investor event on December 10th at 4 p.m. CST / 5 p.m. EST / 23:00 CET in conjunction with #ASH22 to provide an update on our AFM13 development strategy. Please find more information here: https://t.co/9rWHq7GpTW

[Affimed @affimed]

Our CEO, Adi Hoess will be giving a talk at this year’s @Jefferies Healthcare Conference in London. Join his presentation via our webcast https://t.co/Ao94uihZM6 on Wednesday, November 16th, 2022, at 7:55 EST/ 13:55 CET. #JefferiesHealthcare

[Affimed @affimed]

Today, we announce our Q3 2022 financial results and provide a corporate update. Access our Investor's call at 8:30 a.m. EST / 14:30 CET with the following link: https://t.co/QNVHTasjoS - A replay will be available for 30 days. To the press release: https://t.co/xSHL1YyzUT

[Affimed @affimed]

Listen to our CSO, Arndt Schottelius giving a talk #PEGSEurope on the early clinical outcomes of the AFM13-NK cell combination trial on Nov 15th, at 9:30 CET in Barcelona. Find the agenda here https://t.co/pGDqeACui9 or learn about our recent update here: https://t.co/fvnET55eL7